|
Video: What is a Stock Split?
|
|
TRACON Pharmaceuticals is a biopharmaceutical company. Co. has a collaboration and clinical trial agreement for the development of envafolimab, an investigational PD-L1 single-domain antibody for the treatment of sarcoma in North America. Co.'s other clinical stage oncology product candidates include YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 antibody, TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors, and TJ004309, which is a CD73 antibody in Phase 1 clinical development for the treatment of solid tumors. According to our TRACON Pharmaceuticals stock split history records, TRACON Pharmaceuticals has had 1 split. | |
|
TRACON Pharmaceuticals (TCON) has 1 split in our TRACON Pharmaceuticals stock split history database. The split for TCON took place on November 08, 2019. This was a 1 for 10 reverse split, meaning for each 10 shares of TCON owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as TRACON Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the TRACON Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into TRACON Pharmaceuticals shares, starting with a $10,000 purchase of TCON, presented on a split-history-adjusted basis factoring in the complete TRACON Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/02/2015 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$95.00 |
|
End price/share: |
$0.43 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.55% |
|
Average Annual Total Return: |
-44.55% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$45.27 |
|
Years: |
9.15 |
|
|
|
Date |
Ratio |
11/08/2019 | 1 for 10 |
|
|